派林生物(000403) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥665,741,511.82, representing a 32.51% increase compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥183,058,248.30, up 42.42% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.2499, reflecting a 42.15% increase compared to the same period last year[5] - Total revenue for Q3 2023 was CNY 1,374,813,312.16, a decrease of 7.97% compared to CNY 1,493,472,266.77 in Q3 2022[16] - The company's net profit for Q3 2023 was CNY 325,813,319.79, a decrease of 7.0% compared to CNY 350,545,112.47 in Q3 2022[17] - Operating profit for Q3 2023 was CNY 372,635,563.90, down 6.4% from CNY 398,213,050.72 in Q3 2022[17] - Total revenue from operating activities was CNY 1,652,733,408.58, an increase of 6.5% compared to CNY 1,551,656,692.88 in Q3 2022[20] - The company reported a total comprehensive income of CNY 325,834,307.14 for Q3 2023, compared to CNY 350,621,759.92 in Q3 2022[18] - Basic earnings per share for Q3 2023 were CNY 0.4460, a decrease from CNY 0.4784 in the same quarter last year[18] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥8,244,609,207.18, a 3.29% increase from the end of the previous year[5] - Total assets as of September 30, 2023, amounted to CNY 8,244,609,207.18, up from CNY 7,982,324,465.77 at the beginning of the year[15] - Current assets totaled CNY 3,072,354,748.78, slightly increasing from CNY 3,046,975,789.60 at the start of the year[14] - Non-current assets reached CNY 5,172,254,458.40, compared to CNY 4,935,348,676.17 at the beginning of the year, indicating a growth of 4.81%[15] - Total liabilities decreased slightly to CNY 1,115,349,619.22 from CNY 1,121,197,229.65[16] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥269,739,930.34, down 9.81% year-on-year[5] - Cash flow from operating activities generated a net amount of CNY 225,733,198.18, down 18.4% from CNY 276,804,122.72 in the previous year[20] - The net cash flow from financing activities decreased by 75.57% to ¥28,452,153.67, primarily due to increased loan repayments[10] - The net cash flow from financing activities was CNY 28,452,153.67, a decrease from CNY 116,480,692.06 in Q3 2022[20] - The net increase in cash and cash equivalents for Q3 2023 was -218,461,879.92, compared to -74,875,006.98 in the same period last year[21] - The beginning balance of cash and cash equivalents was 1,000,535,509.13, up from 885,158,029.96 year-over-year[21] - The ending balance of cash and cash equivalents for Q3 2023 was 782,073,629.21, a decrease from 810,283,022.98 in the previous year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,723, with the top ten shareholders holding a combined 52.43% of shares[11] - The largest shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, holds 20.99% of shares, totaling 153,752,812 shares[11] - Harbin Tongzhi Cheng Technology Development Co., Ltd. is the second-largest shareholder with 10.97%, holding 80,381,128 shares[11] - The company has a total of 40,190,564 shares under lock-up conditions held by Harbin Tongzhi Cheng Technology Development Co., Ltd.[11] - The company has a total of 11,458,389 shares held by the private equity fund Heilongjiang Lanxiang Biotechnology Consulting Co., Ltd.[11] Corporate Developments - The company reported a significant increase in trading financial assets, which rose by 56.58% to ¥661,450,855.96 due to purchases of cash management products[8] - Accounts receivable decreased by 37.07% to ¥526,018,526.67, attributed to higher collections from previous sales[8] - Inventory increased by 53.50% to ¥957,335,186.62, driven by an increase in raw materials and product stock[8] - The company reported a 221.78% increase in non-operating expenses, totaling ¥5,849,963.67, mainly due to increased donation expenses and asset disposals[10] - The company has announced the progress of share repurchase, with the implementation results disclosed on July 22, 2023[13] - The company received a clinical trial application acceptance notice from the National Medical Products Administration for its subsidiary's drug on August 24, 2023[13] - The company obtained a single plasma collection license for Bayannaoer Paisifiko Plasma Co., Ltd. on August 8, 2023[13] - The company reported that the first major shareholder's concerted action, Shen Heping, plans to increase shareholding[13] - The company has disclosed a special report on the use of raised funds for the first half of 2023 on August 24, 2023[13] Research and Development - Research and development expenses increased to CNY 53,761,401.55, up 21.5% from CNY 44,124,749.34 in the same period last year[17] Audit Status - The Q3 2023 report has not been audited[21]